Watertown, United States
EnPlusOne Biosciences, founded in 2022, is emerging as a transformative force within the Biotechnology and Life Sciences industries. The company’s slogan, "Harnessing the power and flexibility of enzymes to deliver RNA to the world", encapsulates its mission to revolutionize RNA synthesis.
Leveraging its proprietary ezRNA™ synthesis platform, EnPlusOne is innovating with a stepwise approach that allows for the incorporation of a wide range of nucleotide modifications. This platform is pivotal in providing sustainable, commercial-scale delivery of therapeutic RNA, further broadening the potential applications in RNA solutions.
Headquartered in the United States, EnPlusOne secured a $12.00M Seed Round investment on 30 September 2022, with significant backing from investors such as Breakout Ventures, Coatue, and Northpond Ventures. Such funding underscores investor confidence in its cutting-edge technologies and growth potential.
